Programming the immune checkpoint to treat hematologic malignancies

References

• Parish CR. Cancer immunotherapy: The past, the present and the future*. Immunol Cell Biol. 2003;81(2):106–113.
   PubMed Web of Science ®Google Scholar
• Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):djv048.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(6):690–697.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(3):251–257.
   PubMed Web of Science ®Google Scholar
• Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15(9):1019–1026.
   PubMed Web of Science ®Google Scholar
• Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–176.
   PubMed Web of Science ®Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N. Engl. J. Med. 2015;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Gugliotta G, Breccia M, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29(9):1823–1831.
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–384.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(18):2004–2012.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319.
   PubMed Web of Science ®Google Scholar
• McGray AJR, Hallett R, Bernard D, et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther J Am Soc Gene Ther. 2014;22(1):206–218.
   PubMed Web of Science ®Google Scholar
• Thangavelu G, Parkman JC, Ewen CL, et al. Programmed death-1 is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasis. J Autoimmun. 2011;36(3–4):301–312.
   PubMed Web of Science ®Google Scholar
• Verhagen J, Genolet R, Britton GJ, et al. CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proc Natl Acad Sci. 2013;110(3):E221–230.
   Google Scholar
• Chuang E, Lee KM, Robbins MD, et al. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. J Immunol. 1999;162(3):1270–1277.
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Komarovskaya M. CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother. 2002;25(6):455–468.
   PubMed Web of Science ®Google Scholar
• Hawkes EA, Grigg A, Chong G. Programmed cell death-1 inhibition in lymphoma. Lancet Oncol. 2015;16(5):e234–245.
   PubMed Web of Science ®Google Scholar
• Tang L, Bai J, Chung C-S, et al. Programmed cell death receptor ligand 1 modulates the regulatory T cells’ capacity to repress shock/sepsis-induced indirect acute lung injury by recruiting phosphatase SRC homology region 2 domain-containing phosphatase 1. Shock Augusta Ga. 2015;43(1):47–54.
   PubMed Web of Science ®Google Scholar
• Sheppard K-A, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCΘ. FEBS Lett. 2004;574(1–3):37–41.
   PubMed Web of Science ®Google Scholar
• Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata. Cancer. 2007;109(8):1499–1505.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Z, Liu Y, et al. Programmed death-ligand 1 (PD-L1) may play a role in malignant glioma infiltration. Med Hypotheses. 2015;85:127–129.
   PubMed Web of Science ®Google Scholar
• Bishop JL, Sio A, Angeles A, et al. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. 2014;6(1):234–242.
   Web of Science ®Google Scholar
• Bigelow E, Bever KM, Xu H, et al. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp. 2013;(71). pii: 4059.
   Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–856.
   PubMed Web of Science ®Google Scholar
• Abiko K, Matsumura N, Hamanishi J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112(9):1501–1509.
   PubMed Web of Science ®Google Scholar
• Ota K, Azuma K, Kawahara A, et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:4014–4021.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by Murine T cells and APC. J Immunol. 2002;169(10):5538–5545.
   PubMed Web of Science ®Google Scholar
• Rodig N, Ryan T, Allen JA, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003;33(11):3117–3126.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci. 2007;104(9):3360–3365.
   PubMed Web of Science ®Google Scholar
• Winograd R, Byrne KT, Evans RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 2015;3(4):399–411.
   PubMed Web of Science ®Google Scholar
• Okamura T, Sumitomo S, Morita K, et al. TGF-β3-expressing CD4+CD25−LAG3+ regulatory T cells control humoral immune responses. Nat Commun. 2015;6:6329.
   PubMed Web of Science ®Google Scholar
• Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917–927.
   PubMed Web of Science ®Google Scholar
• Anderson AC. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res. 2014;2(5):393–398.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117(17):4501–4510.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187–2194.
   PubMed Web of Science ®Google Scholar
• Gorman JV, Colgan JD. Regulation of T cell responses by the receptor molecule Tim-3. Immunol Res. 2014;59(1–3):56–65.
   PubMed Web of Science ®Google Scholar
• DeKruyff RH, Bu X, Ballesteros A, et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol. 2010;184(4):1918–1930.
   PubMed Web of Science ®Google Scholar
• Chiba S, Baghdadi M, Akiba H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832–842.
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245–1252.
   PubMed Web of Science ®Google Scholar
• Gao X, Zhu Y, Li G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE. 2012;7(2):e30676.
   PubMed Web of Science ®Google Scholar
• Xu L, Huang Y, Tan L, et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 2015;29:635–641.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Pagliano O, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res. 2014;74(4):1045–1055.
   PubMed Web of Science ®Google Scholar
• Huang X, Bai X, Cao Y, et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med. 2010;207(3):505–520.
   PubMed Web of Science ®Google Scholar
• Kong Y, Zhang J, Claxton DF, et al. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015;5:e330.
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang AY. Novel immune check-point regulators in tolerance maintenance. Immunol Toler. 2015:18;6:421.
   Google Scholar
• Liu J, Yuan Y, Chen W, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A. 2015;112(21):6682–6687.
   PubMed Web of Science ®Google Scholar
• Lines JL, Sempere LF, Broughton T, et al. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res. 2014;2(6):510–517.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. OncoImmunology. 2014;3(10):e957994.
   PubMed Web of Science ®Google Scholar
• Berthon C, Fontenay M, Corm S, et al. Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leuk Res. 2013;37(5):573–579.
   PubMed Web of Science ®Google Scholar
• Ninomiya S, Hara T, Tsurumi H, et al. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol. 2011;90(4):409–416.
   PubMed Web of Science ®Google Scholar
• Jitschin R, Braun M, Büttner M, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124(5):750–760.
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27(45):5932–5943.
   PubMed Web of Science ®Google Scholar
• Hilpert J, Grosse-Hovest L, Grünebach F, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol Baltim Md 1950. 2012;189(3):1360–1371.
   Google Scholar
• Igarashi T, Wynberg J, Srinivasan R, et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004;104(1):170–177.
   PubMed Web of Science ®Google Scholar
• Gras Navarro A, Björklund AT, Chekenya M. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol. 2015;6:202
   PubMed Web of Science ®Google Scholar
• Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878–4884.
   PubMed Web of Science ®Google Scholar
• Korde N, Carlsten M, Lee M-J, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica. 2014;99(6):e81–e83.
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100(14):8372–8377.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti–CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell Non–Hodgkin lymphoma. Clin Cancer Res. 2009;15(20):6446–6453.
   PubMed Web of Science ®Google Scholar
• Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581–1588.
   PubMed Web of Science ®Google Scholar
• Pedicord VA, Cross JR, Montalvo-Ortiz W, et al. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. J Immunol. 2015;194(5):2089–2098.
   PubMed Web of Science ®Google Scholar
• Yoshimoto Y, Suzuki Y, Mimura K, et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PloS One. 2014;9(3):e92572.
   PubMed Web of Science ®Google Scholar
• Ciszak L, Frydecka I, Wolowiec D, et al. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody. Tumour Biol. 2015:1–15. DOI:10.1007/s13277-015-4217-1. [Epub ahead of print]
   Web of Science ®Google Scholar
• Schmidt EM, Wang CJ, Ryan GA, et al. CTLA-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol. 2009;182(1):274–282.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239–245.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311–4318.
   PubMed Web of Science ®Google Scholar
• Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31(33):4199–4206.
   PubMed Web of Science ®Google Scholar
• Croft M, So T, Duan W, et al. The significance of OX40 and OX40L to T cell biology and immune disease. Immunol Rev. 2009;229(1):173–191.
   PubMed Web of Science ®Google Scholar
• Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res. 2014;2(2):142–153.
   PubMed Web of Science ®Google Scholar
• Voo KS, Foglietta M, Percivalle E, et al. Selective targeting of toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer J Int Cancer. 2014;135(12):2834–2846.
   PubMed Web of Science ®Google Scholar
• Bartkowiak T, Curran MA. 4-1BB agonists: multi-potent potentiators of tumor immunity. Front Oncol. 2015;5:117.
   PubMed Web of Science ®Google Scholar
• Lee S-W, Park Y, Eun S-Y, et al. Cutting edge: 4-1BB controls regulatory activity in dendritic cells through promoting optimal expression of retinal dehydrogenase. J Immunol. 2012;189(6):2697–2701.
   PubMed Web of Science ®Google Scholar
• Clouthier DL, Watts TH. Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection. Cytokine Growth Factor Rev. 2014;25(2):91–106.
   PubMed Web of Science ®Google Scholar
• Khattri R, Cox T, Yasayko S-A, et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4(4):337–342.
   PubMed Web of Science ®Google Scholar
• Zhan Y, Gerondakis S, Coghill E, et al. Glucocorticoid-induced TNF receptor expression by T cells is reciprocally regulated by NF-κB and NFAT. J Immunol. 2008;181(8):5405–5413.
   PubMed Web of Science ®Google Scholar
• Kohm AP, Podojil JR, Williams JS, et al. CD28 regulates glucocorticoid-induced TNF receptor family-related gene expression on CD4+ T cells via IL-2-dependent mechanisms. Cell Immunol. 2005;235(1):56–64.
   PubMed Web of Science ®Google Scholar
• Stephens GL, McHugh RS, Whitters MJ, et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol. 2004;173(8):5008–5020.
   PubMed Web of Science ®Google Scholar
• Buechele C, Baessler T, Wirths S, et al. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia. 2012;26(5):991–1000.
   PubMed Web of Science ®Google Scholar
• Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15(1):69–77.
   PubMed Web of Science ®Google Scholar
• Paydas S, Bagir E, Seydaoglu G, et al. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol. 2015;94(9):1545–1552.
   PubMed Web of Science ®Google Scholar
• Herbaux C, Gauthier J, Brice P, et al. Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin’s lymphoma after allogeneic hematopoietic cell transplantation: a study from the Lysa and SFGM-TC. In: 3979 Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin’s lymphoma after allogeneic hematopoietic cell transplantation: a study from the Lysa and SFGM-TC; Orlando (FL); 2015.
   Google Scholar
• Wang L, Qian J, Lu Y, et al. Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica. 2013;98(9):1458–1466.
   PubMed Web of Science ®Google Scholar
• Klingemann H, Grodman C, Cutler E, et al. Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell enriched infusions. Transfusion (Paris). 2013;53(2):412–418.
   Web of Science ®Google Scholar
• Zhao S, Xing Y, Natkunam Y. Use of CD137 ligand expression in the detection of small B-cell lymphomas involving the bone marrow. Hum Pathol. 2014;45(5):1024–1030.
   PubMed Web of Science ®Google Scholar
• Xerri L, Chetaille B, Seriari N, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol. 2008;39(7):1050–1058.
   PubMed Web of Science ®Google Scholar
• Dorfman DM, Brown JA, Shahsafaei A, et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30(7):802–810.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114(10):2149–2158.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Vick E, Huber B, et al. Aurora plus PI3K inhibition abrogates PD-L1 induction in peripheral T-cell Non-Hodgkin lymphoma. Blood. 2015;126(23):1560–1560.
   Google Scholar
• Novak M, Prochazka V, Turcsanyi P, et al. Numbers of CD8+PD-1+ and CD4+PD-1+ cells in peripheral blood of patients with chronic lymphocytic leukemia are independent of binet stage and are significantly higher compared to healthy volunteers. Acta Haematol. 2015;134(4):208–214.
   PubMed Web of Science ®Google Scholar
• Grzywnowicz M, Karczmarczyk A, Skorka K, et al. Expression of programmed death 1 ligand in different compartments of chronic lymphocytic leukemia. Acta Haematol. 2015;134(4):255–262.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Qi W, Cooke L, et al. Targeting aurora kinase in aggressive B-cell Non-Hodgkin’s lymphomas. Blood. 2009;114(22):284–284.
   Google Scholar
• Kosmaczewska A, Ciszak L, Suwalska K, et al. CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia. 2005;19(2):301–304.
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–562.
   PubMed Web of Science ®Google Scholar
• Ding W, Dong H, Call T, et al. PD-1 blockade with pembrolizumab (MK-3475) in relapsed/refractory CLL including richter transformation: an early efficacy report from a phase 2 trial (MC1485) [Internet]. In: 834 PD-1 blockade with pembrolizumab (MK-3475) in relapsed/refractory CLL including richter transformation: an early efficacy report from a phase 2 trial (MC1485); Orlando (FL); 2015. [cited 2016 Jan 2]. Available from: https://ash.confex.com/ash/2015/webprogram/Paper84816.html.
   Google Scholar
• Christiansson L, Söderlund S, Svensson E, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PloS One. 2013;8(1):e55818.
   PubMed Web of Science ®Google Scholar
• Mumprecht S, Schürch C, Schwaller J, et al. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009;114(8):1528–1536.
   PubMed Web of Science ®Google Scholar
• Porkka K, Mauro MJ, Lipton JH, et al. An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML). In: ASCO Meeting Abstracts. Chicago (IL): American Society of Clinical Oncology; 2014.
   Google Scholar
• Curti A, Ruggeri L, D’Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011;118(12):3273–3279.
   PubMed Web of Science ®Google Scholar
• Vey N, Bourhis J-H, Boissel N, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood. 2012;120(22):4317–4323.
   PubMed Web of Science ®Google Scholar
• Davids MS, Kim HT, Costello CL, et al. A multicenter phase I/Ib study of ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Blood. 2015;126(23):860–860.
   Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280–1288.
   PubMed Web of Science ®Google Scholar
• Kondo A, Yamashita T, Tamura H, et al. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood. 2010;116(7):1124–1131.
   PubMed Web of Science ®Google Scholar
• Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125(22):3393–3400.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Zeidner JF, Duffield A, et al. Stabilization of myelodysplastic syndromes (MDS) following hypomethylating agent (HMAs) failure using the immune checkpoint inhibitor ipilimumab: a phase I trial. Blood. 2015;126(23):1666–1666.
   Google Scholar
• Gorgun G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple Myeloma. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:4607–4618.
   PubMed Web of Science ®Google Scholar
• Chung DJ, Pronschinske KB, Shyer JA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2015;4(1):61–71.
   PubMed Web of Science ®Google Scholar
• Kong YM, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front Immunol [Internet]. 2014;5. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032988/
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, McArthur GA, Smyth MJ. Radiotherapy complements immune checkpoint blockade. Cancer Cell. 2015;27(4):437–438.
   PubMed Web of Science ®Google Scholar